SCHEMBL1818138

SCHEMBL1818138

N#Cc1nc[c]o1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1821091 0.55
SCHEMBL3243034 0.54
SCHEMBL446938 0.51
SCHEMBL2046066 0.51
SCHEMBL8382035 0.48
SCHEMBL29350921 0.48 ALDH1A1 (0.38)
SCHEMBL151679 0.46
SCHEMBL28061488 0.46 CLK4 (0.38)
SCHEMBL24676486 0.42
SCHEMBL45942 0.41 CA2 (0.69)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221354-A1 IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY EMBLEM TECHNOLOGY TRANSFER GMBH (DE) 2014-08-07 US claimed
EP-2691392-A1 IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY EMBLEM Technology Transfer GmbH (DE) 2014-02-05 EP claimed
WO-2012130322-A1 IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY ELARA PHARMACEUTICALS GMBH (DE) 2012-10-04 WO claimed
WO-2011057892-A1 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES ELARA PHARMACEUTICALS GMBH (DE) 2011-05-19 WO claimed
EP-0366304-B1 Heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1998-04-15 EP claimed
US-5166357-A Nitrogen heterocylic compounds used in treatment of dementia in mammals BEECHAM GROUP P.L.C. (GB) 1992-11-24 US claimed
EP-0366304-A2 Heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1990-05-02 EP claimed
US-10959432-B2 Microbiocidal oxadiazole derivatives SYNGENTA PARTICIPATIONS AG (CH) 2021-03-30 US disclosed
US-10757941-B2 Microbiocidal oxadiazole derivatives SYNGENTA PARTICIPATIONS AG (CH) 2020-09-01 US disclosed
US-20200267986-A1 Microbiocidal Oxadiazole Derivatives SYNGENTA PARTICIPATIONS AG (CH) 2020-08-27 US disclosed
US-10687533-B2 Microbiocidal oxadiazole derivatives SYNGENTA PARTICIPATIONS AG (CH) 2020-06-23 US disclosed
EP-3439477-B1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2020-05-06 EP disclosed
US-20190345150-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2019-11-14 US disclosed
WO-2011057892-A1 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES ELARA PHARMACEUTICALS GMBH (DE) 2011-05-19 WO disclosed
EP-0366304-B1 Heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1998-04-15 EP disclosed
US-5234946-A Anticholesterol, antilipemic BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-10 US disclosed
EP-0318860-B1 SUBSTITUTED ALKYLAMINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-06-16 EP disclosed
US-5166357-A Nitrogen heterocylic compounds used in treatment of dementia in mammals BEECHAM GROUP P.L.C. (GB) 1992-11-24 US disclosed
EP-0366304-A2 Heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1990-05-02 EP disclosed
EP-0318860-A2 Substituted alkylamine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1989-06-07 EP disclosed